Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2651-2660

  Plotnicky, Hélène ^a   Siegrist, Claire Anne ^b   Aubry, Jean Pierre ^a   Bonnefoy, Jean Yves ^a   Corvaïa, Nathalie ^a   Nguyen, Thien Ngoc ^a   Power, Ultan F ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

BBG2Na; Enhanced immunopathology; Neonatal immunization; RSV

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; CRL 8941; FORMALDEHYDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; PROTEIN BBG2NA; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TITERMAX; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; EOSINOPHILIA; IMMUNIZATION; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; LUNG ALVEOLUS CELL; LUNG INFECTION; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE STRAIN; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TH1 CELL; TH2 CELL; VIRUS INFECTION;

EID: 0038402666     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00055-0     Document Type: Article

References (36)

1. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven; 1996. p. 1313-51.
2. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K.et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1969;422-434.
3. Gershwin L.J., Schelegle E.S., Gunther R.A., Anderson M.L., Woolums A.R., Larochelle D.R.et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine. 16:1998;1225-1236.
4. Kakuk T.J., Soike K., Brideau R.J., Zaya R.M., Cole S.L., Zhang J.Y.et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J. Infect. Dis. 167:1993;553-561.
5. Byrd L.G., Prince G.A. Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 25:1997;1363-1368.
6. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L.et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:1986;721-728.
7. Vaux-Peretz F., Chapsal J.M., Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in BALB/c mice. Vaccine. 10:1992;113-118.
8. Murphy B.R., Sotnikov A., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
9. Hancock G.E., Speelman D.J., Heers K., Bortell E., Smith J., Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:1996;7783-7791.
10. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:1996;2852-2860.
11. Graham B.S., Henderson G.S., Tang Y.-W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:1993;2032-2040.
12. Waris M.E., Tsou C., Erdman D.D., Day D.B., Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge of BALB/c mice immunized with formalin-inactivated RSV. J. Virol. 71:1997;6935-6939.
13. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicholson C., Melero J.A., Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine. 19:2000;1038-1046.
14. Connors M., Giese N.A., Kulkarni A.B., Firestone C.-Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:1994;5321-5325.
15. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., Stahl S.et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 230:1997;155-166.
16. Power U.F., Nguyen T.N., Rietveld E., de Swart R.L., Groen J., Osterhaus A.D.M.E.et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184:2001;1456-1460.
17. Libon C., Corvaïa N., Haeuw J.F., Nguyen T.N., Stahl S., Bonnefoy J.Y.et al. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G133-230 RSV-A protein. Vaccine. 17:1999;406-414.
18. Corvaïa N., Tournier P., Nguyen T.N., Haeuw J.F., Power U.F., Binz H.et al. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2Na, in aluminum hydroxide. J. Infect. Dis. 176:1997;560-569.
19. Plotnicky-Gilquin H., Huss T., Aubry J.-P., Haeuw J.-F., Beck A., Bonnefoy J.-Y.et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology. 258:1999;128-140.
20. Power U.F., Huss T., Michaud V., Plotnicky-Gilquin H., Robert A., Bonnefoy J.-Y.et al. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV or BBG2Na-immunized mice. J. Virol. 75:2001;1221-1230.
21. Siegrist C.A. Neonatal and early life vaccinology. Vaccine. 19:2001;3331-3346.
22. Martinez X., Li X., Kovarik J., Klein M., Lambert P.H., Siegrist C.A. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur. J. Immunol. 29:1999;3390-3400.
23. Brandt C., Power U.F., Plotnicky-Gilquin H., Huss T., Nguyen T.N., Lambert P.H.et al. Protective immunity against respiratory syncytial virus in early life after murine maternal and neonatal vaccination with the recombinant G fusion protein BBG2Na. J. Infect. Dis. 176:1997;884-891.
24. Siegrist C.A., Plotnicky-Gilquin H., Cordova M., Berney M., Bonnefoy J.-Y., Nguyen T.N.et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J. Infect. Dis. 179:1999;1326-1333.
25. Siegrist C.A. Vaccination in the neonatal period and early infancy. Int. Rev. Immunol. 19:2000;195-219.
26. Trudel M., Nadon F., Seguin C., Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virol. 185:1991;749-757.
27. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today. 14:1993;281-284.
28. Barrios C., Brawand P., Berney M., Brandt C., Lambert P.H., Siegrist C.A. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. J. Immunol. 26:1996;1489-1496.
29. Adkins B. T-cell function in newborn mice and human. Immunol. Today. 20:1999;330-335.
30. Belshe R.B., Van Voris L.P., Mufson M.A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J. Infect. Dis. 145:1982;311-319.
31. Murphy B.R., Alling D.W., Snyder M.H., Walsh E.E., Prince G.A., Chanock R.M.et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:1986;894-898.
32. Bangham C.R. Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology. 59:1986;37-41.
33. Stott E.J., Taylor G., Ball L.A., Anderson K., Young K.K., King A.M.et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:1987;3855-3861.
34. Vaux-Peretz F., Meignier B. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus. Vaccine. 8:1990;543-548.
35. Kovarik J., Bozzotti P., Love-Homan L., Pihlgren M., Davis H.L., Lambert P.H.et al. CpG oligonucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162:1999;1611-1617.
36. Hussell T., Spender L.C., Georgiou A., O'Garra A., Openshaw P.J. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J. Gen. Virol. 77:1996;2447-2455.